Going forward, it will be intriguing to examine whether metabolic modulators that have shown efficacy in modulating NLRX1-dependent functions, such as NX-1 or rapamycin, can be used to mitigate diseases such as MS or COPD. Here, NLRX1 is linked to myeloid sarcoma.